Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1996 May 25;312(7042):1321–1325. doi: 10.1136/bmj.312.7042.1321

Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.

A H Briggs 1, M J Sculpher 1, R P Logan 1, J Aldous 1, M E Ramsay 1, J H Baron 1
PMCID: PMC2350996  PMID: 8646042

Abstract

OBJECTIVE--To assess the cost effectiveness of screening for and eradicating Helicobacter pylori in patients under 45 years of age presenting with dyspepsia. DESIGN--A decision analytic model composed of a decision tree to represent the epidemiology of dyspepsia and a Markov process to model the outcomes of treatment. PATIENTS--Patients under the age of 45 years presenting to their general practitioner with (peptic type) dyspepsia. INTERVENTIONS--Conventional empirical treatment with healing and maintenance doses of cimetidine v eradication treatment solely in patients with confirmed peptic ulcer; and conventional empirical treatment for all dyspeptic patients compared with the use of a serology test to identify patients with H pylori, who then receive endoscopy to investigate the presence of peptic ulcer disease and, when disease is found, are given eradication treatment with a breath test to confirm successful eradication. MAIN OUTCOME MEASURES--Expected cumulative costs over a period of 10 years. The proportion of time patients spend without a recurrent ulcer. RESULTS--After receiving eradication treatment, patients with confirmed ulcer spend an average of 99% of their time free from recurrent ulcer disease compared with 95% after treatment with cimetidine. Eradication treatment costs less than that with cimetidine. When the initial cost of identifying appropriate patients to receive eradication treatment is added to the analysis, however, these cost savings take almost eight years to accrue. CONCLUSIONS--Enthusiasm for introducing testing for and eradication of H pylori for dyspeptic patients in general practice should be tempered by an awareness that cost savings may take many years to realise.

Full text

PDF
1321

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Axon A. T., Bell G. D., Jones R. H., Quine M. A., McCloy R. F. Guidelines on appropriate indications for upper gastrointestinal endoscopy. Working Party of the Joint Committee of the Royal College of Physicians of London, Royal College of Surgeons of England, Royal College of Anaesthetists, Association of Surgeons, the British Society of Gastroenterology, and the Thoracic Society of Great Britain. BMJ. 1995 Apr 1;310(6983):853–856. doi: 10.1136/bmj.310.6983.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bardhan K. D. Refractory duodenal ulcer. Gut. 1984 Jul;25(7):711–717. doi: 10.1136/gut.25.7.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bell G. D., Powell K. U., Burridge S. M., Harrison G., Rameh B., Weil J., Gant P. W., Jones P. H., Trowell J. E. Reinfection or recrudescence after apparently successful eradication of Helicobacter pylori infection: implications for treatment of patients with duodenal ulcer disease. Q J Med. 1993 Jun;86(6):375–382. [PubMed] [Google Scholar]
  4. Briggs A., Sculpher M., Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994 Mar-Apr;3(2):95–104. doi: 10.1002/hec.4730030206. [DOI] [PubMed] [Google Scholar]
  5. Clausen M. R., Franzmann M. B., Holst C., Sørensen T. I., Christoffersen P., Matzen P., Krag E. Longitudinal study of influence of Helicobacter pylori on current risk of duodenal ulcer relapse. The Hvidovre Ulcer Project Group. Scand J Gastroenterol. 1992 May;27(5):421–426. doi: 10.3109/00365529209000099. [DOI] [PubMed] [Google Scholar]
  6. Edenholm M., Gustavsson R., Jansson O., Lingfors H., Nilsson O., Söderlind T., Titusson L., Thulin A. Endoscopic findings in patients with ulcer-like dyspepsia. Scand J Gastroenterol Suppl. 1985;109:163–167. doi: 10.3109/00365528509103953. [DOI] [PubMed] [Google Scholar]
  7. Katz K. D., Hollander D. Practical pharmacology and cost-effective management of peptic ulcer disease. Am J Surg. 1992 Mar;163(3):349–359. doi: 10.1016/0002-9610(92)90021-i. [DOI] [PubMed] [Google Scholar]
  8. Labenz J., Börsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Am J Gastroenterol. 1994 Oct;89(10):1785–1788. [PubMed] [Google Scholar]
  10. Patel P., Mendall M. A., Khulusi S., Molineaux N., Levy J., Maxwell J. D., Northfield T. C. Salivary antibodies to Helicobacter pylori: screening dyspeptic patients before endoscopy. Lancet. 1994 Aug 20;344(8921):511–512. doi: 10.1016/s0140-6736(94)91899-6. [DOI] [PubMed] [Google Scholar]
  11. Pym B., Sandstad J., Seville P., Byth K., Middleton W. R., Talley N. J., Piper D. W. Cost-effectiveness of cimetidine maintenance therapy in chronic gastric and duodenal ulcer. Gastroenterology. 1990 Jul;99(1):27–35. doi: 10.1016/0016-5085(90)91225-u. [DOI] [PubMed] [Google Scholar]
  12. Sonnenberg A., Townsend W. F., Müller A. D. Evaluation of dyspepsia and functional gastrointestinal disorders: a cost-benefit analysis of different approaches. Eur J Gastroenterol Hepatol. 1995 Jul;7(7):655–659. [PubMed] [Google Scholar]
  13. Sonnenberg F. A., Beck J. R. Markov models in medical decision making: a practical guide. Med Decis Making. 1993 Oct-Dec;13(4):322–338. doi: 10.1177/0272989X9301300409. [DOI] [PubMed] [Google Scholar]
  14. Tytgat G. N. Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther. 1994 Aug;8(4):359–368. doi: 10.1111/j.1365-2036.1994.tb00303.x. [DOI] [PubMed] [Google Scholar]
  15. Veldhuyzen van Zanten S. J., Sherman P. M. Indications for treatment of Helicobacter pylori infection: a systematic overview. CMAJ. 1994 Jan 15;150(2):189–198. [PMC free article] [PubMed] [Google Scholar]
  16. Webb P. M., Knight T., Greaves S., Wilson A., Newell D. G., Elder J., Forman D. Relation between infection with Helicobacter pylori and living conditions in childhood: evidence for person to person transmission in early life. BMJ. 1994 Mar 19;308(6931):750–753. doi: 10.1136/bmj.308.6931.750. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES